Importantly, as the chief brain source of APOE, astrocytes, especially those expressing the APOE4 allele, promote A aggregation, tau pathologies, BBB breakdown, and cerebrovascular dysfunctions (Wang M
Pituitary or Hypothalamic Disorders problems in the pituitary gland or hypothalamus (which regulate the thyroid) can cause secondary or tertiary hypothyroidism
doi: 10.1016/j.jdiacomp.2022.108332 138 RosenstockJFriasJJastreboffAMDuYLouJGurbuzSet al
[DOI] [PubMed] [Google Scholar] 35.Bird T.G., Muller M., Boulter L., Vincent D.F., Ridgway R.A., Lopez-Guadamillas E., Lu W.Y., Jamieson T., Govaere O., Campbell A.D., Ferreira-Gonzalez S., Cole A.M., Hay T., Simpson K.J., Clark W., Hedley A., Clarke M., Gentaz P., Nixon C., Bryce S., Kiourtis C., Sprangers J., Nibbs R.J.B., Van Rooijen N., Bartholin L., McGreal S.R., Apte U., Barry S.T., Iredale J.P., Clarke A.R., Serrano M., Roskams T.A., Sansom O.J., Forbes S.J
Conclusion As we look toward the future of metabolic research in 2026 and beyond, retatrutide represents one of the most exciting scientific advancements in decades
Patients with commercial coverage that includes GLP-1 riders face prior authorization requirements (BMI 30, documented lifestyle modification attempts, comorbidity criteria) and 1224 month coverage caps before transitioning to self-pay or discontinuation
